The purpose of this document is to provide information on prices and suppliers that will help purchasers make informed decisions when buying antiretrovirals (ARVs). This report is a pricing guide and does not include detailed information about the quality of the products listed.
Because developing AIDS drugs for poor children is not profitable, many companies don?t even study the effects of existing or new adult antiretroviral drugs in children. We must make sure that the youngest people living with AIDS are not forgotten.
HIV/AIDS treatment and management are essential components of many MSF programs worldwide. Currently MSF provides antiretroviral therapy (ART) for over 140,000 patients in 27 countries, with about 10,000 of those patients being children. In conjunction with this year’s International AIDS Conference in Mexico City, this document presents MSF’s current “state of play” in providing quality care to people living with HIV/AIDS (PLWHA) in resource-limited settings.